Thank you, Ran Wei. As of the end of March 2025, around 475 million people cumulatively donated RMB 68.8 billion to about 3.47 million patients through our virtual medical cofunding platform. We focus on 3 key [ tests ] this quarter. First, we optimized our process design by introducing an online pledge requirement at the campaign initiation stage. Through this request, we will clearly communicate to -- communicate the platform core orientation to users. Additionally, we have carefully educated users about our social supervision mechanism as well as relevant laws and regulations, much like the health declaration and insurance application. This matter established an [indiscernible] Additionally, we moving on continued to enhance its risk control verification capability through systematic infrastructure improvement this quarter. We delivered standardized verification deadline for 3 high-risk scenarios, housing, vehicle, electric and income. By integrating official verification channels like from traffic management bureaus and local government service platform covering 92% of cities nationwide, we significantly improved the efficiency and quality of risk verification. Regarding the most confirmed issue of bond security, Waterdrop implemented an intelligent monitoring platform combining system [indiscernible] and manual follow-up. For 5 high-risk scenarios, the system can generate optimal risk control solution based on algorithm model. Determine the ideal frequency and timing for human invention, the technological approach have been effectively reduce the risk of misappropriation and ensuring the safety of [indiscernible] bond. In this quarter, health care-related business maintained steady development. The digital clinical trial solutions business with 185 pharmaceuticals and CRO, securing 7 new projects. During the quarter, 822 patients have been enrolled and the cumulative number of enrolled patients reached 11,250. Revenue from digital clinical trial business grew by 11.5% year-over-year. The platform continued to the oncology view, expanding its collaborative project this quarter in psoriasis, [indiscernible], gastrointestinal tumors, thereby strengthen its industry competitiveness. Additionally, leveraging extensive patient database and digital recruitment strategy, the platform achieved [indiscernible] in chronic and rare diseases, earning well recognized recognition. Concurrently, in this quarter, the platform has actively expanded digital omnichannel marketing initiatives, leveraging its [indiscernible] partnered with medical device company to jointly develop an intelligent service system for [indiscernible] base. This product is expected to be launched in the second quarter, collaborating with our partners to enhance the efficiency of patient health management. Now I will hand over to Xiaoying, our Head of Finance Department to discuss our financial performance in this quarter.